Kintara Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Kintara Therapeutics was a San Diego-based biopharmaceutical company (NASDAQ: KTRA) focused on developing new solid tumor cancer therapies. Its lead program was REM-001, a second-generation photodynamic therapy agent being studied in an open-label 15-patient trial in cutaneous metastatic breast cancer.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Merger agreement with TuHURA
In April 2024 Kintara entered a definitive merger agreement with TuHURA Biosciences, a Phase 3 registration-stage immune-oncology company developing technologies to overcome resistance to cancer immunotherapy.
- Merger completed
On October 17, 2024 the merger closed: the combined company operates as TuHURA Biosciences, Inc. (NASDAQ: HURA). Post-merger, Kintara equityholders owned about 2.85% of the combined company (up to 5.45% if REM-001 milestones are met), with TuHURA holders owning the rest - a reverse merger.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.